Frontlight ResearchEarly access
SuspendedPhase 1
Safety and Activity Study of HER2-Targeted Dual Switch CAR-T Cells (BPX-603) in Subjects With HER2-Positive Solid Tumors
Key facts
- Who runs it
- Bellicum Pharmaceuticals
- Where
- Atlanta, Buffalo, Chicago, Duarte, Hackensack, Houston, and La Jolla, United StatesSee the 7 locations
- Trial code
- Status
- Suspended
- Phase
- Phase 1
- People taking part
- 220 people, planned
- Started
- 7 Dec 2020
- Expected to end
- 2 Jan 2027
- Type of study
- Interventional
- Treatments tested
- chimeric antigen receptor (CAR) T cell therapy
- Record updated
- 20 April 2023
- Why it stopped
- Due to a Dose Limiting Toxicity in another sister trial with same technology.
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
Show the full registry criteria (14)Hide the full registry criteria
Who can take part
- Documented evidence of HER2 amplification/overexpression by local testing
- Histologically or cytologically confirmed diagnosis of a locally advanced unresectable or metastatic HER2+ solid tumor malignancy for which standard treatment is no longer effective, does not exist, or subject is ineligible
- Subjects with a solid tumor malignancy for which HER2-targeted therapy is approved as a standard treatment (e.g., breast, gastric cancers) must have received prior treatment with approved HER2-directed therapy
- Measurable disease (at least one target lesion) per RECIST v1.1
- Life expectancy > 12 weeks
- ECOG 0-1
- Adequate organ function
Who cannot take part
- Prior CAR T cell or other genetically-modified T cell therapy
- Impaired cardiac function or clinically significant cardiac disease
- Symptomatic intrinsic lung disease or those with extensive tumor involvement of the lungs
- Severe intercurrent infection
- Known HIV positivity
- Symptomatic, untreated, or actively progressing central nervous system metastases
- Pregnant or breastfeeding
7 locations in United States
- Winship Cancer Institute at Emory UniversityAtlanta, United States
- Roswell Park Cancer InstituteBuffalo, United States
- University of ChicagoChicago, United States
- City of Hope National Medical CenterDuarte, United States
- John Theurer Cancer Center, Hackensack University Medical CenterHackensack, United States
- The University of Texas MD Anderson Cancer CenterHouston, United States
- University of California San Diego (UCSD)La Jolla, United States
What happens in this trial
What the trial wants to find out
This is a Phase 1/2, open-label, multicenter, non-randomized study to investigate the safety, tolerability, and clinical activity of HER2-specific dual-switch CAR-T cells, BPX-603, administered with rimiducid to subjects with previously treated, locally advanced or metastatic solid tumors which are HER2 amplified/overexpressed.
The group in the trial
- HER2-targeted dual-switch CAR-T cellsTreatment being tested
Subjects will receive one dose of BPX-603 on Day 1, followed by rimiducid IV infusion weekly (as tolerated) starting on Day 8 and continued until treatment discontinuation criteria are met.
Treatment: chimeric antigen receptor (CAR) T cell therapy
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Phase 1/2, Open-Label, Multicenter, Non-Randomized, Safety and Activity Study of HER2-Targeted Dual Switch CAR-T Cells (BPX-603) In Subjects With Previously Treated Advanced HER2-Positive Solid Tumors
- Record updated
- 20 April 2023